There are 2789 resources available
1399P - Risk factors for body weight loss after gastrectomy for gastric cancer analysed from the JCOG1001 phase III trial
Presenter: Takanobu Yamada
Session: ePoster Display
1294P - 18F-FDG PET-TC derived parameters as a tool to select pembrolizumab single agent or in combination with chemotherapy in first-line NSCLC
Presenter: Filippo Dall'Olio
Session: ePoster Display
1295P - Prognostic impact of baseline tumor size (BTS) on survival outcomes in patients (pts) with untreated advanced non-small cell lung cancer (NSCLC), PD-L1 ≥50%, treated with pembrolizumab alone
Presenter: Mathilde Bureau
Session: ePoster Display
1302P - Immune signatures of second-line PD-1 immune checkpoint blockade
Presenter: Kenneth O'Byrne
Session: ePoster Display
1303P - A clinical variable based nomogram could predict survival for NSCLC patients receiving atezolizumab
Presenter: Xiaoling Shang
Session: ePoster Display
1304P - Interleukin-6 (IL-6) as a potential predictive marker and a desensitizer for immunotherapy response in non-small cell lung cancer
Presenter: Yan Wang
Session: ePoster Display
1255P - Health utility with tepotinib in patients (pts) with MET exon 14 (METex14) skipping non-small cell lung cancer (NSCLC)
Presenter: Niels Reinmuth
Session: ePoster Display
1256P - Capmatinib safety update in MET dysregulated NSCLC from the GEOMETRY mono-1 trial
Presenter: Rebecca Heist
Session: ePoster Display
1308P - Efficacy and safety of anti-PD-1 therapy plus anlotinib in previously treated advanced NSCLC
Presenter: Xin Lv
Session: ePoster Display